Trevi Therapeutics is frequently analyzed by healthcare and biotechnology investors focusing on specialty clinical-stage pipelines targeting chronic cough and severe pruritus conditions. Bullish analysts highlight the therapeutic potential of its core asset, Haduvio, in addressing significant unmet medical needs. Conversely, cautious market participants emphasize that pre-commercial biotech investments involve high volatility and reliance on positive late-stage clinical data readouts.